Attovia Therapeutics (NASDAQ:ATTO) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a research note issued to investors on Monday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $52.00 target price on the stock.

Separately, Morgan Stanley began coverage on Attovia Therapeutics in a research note on Monday. They issued an “overweight” rating and a $39.00 target price on the stock. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $42.20.

Attovia Therapeutics Trading Up 4.1%

Shares of NASDAQ:ATTO opened at $23.13 on Monday. Attovia Therapeutics has a 1 year low of $16.15 and a 1 year high of $24.32.

Attovia Therapeutics (NASDAQ:ATTO) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter.

Insider Activity at Attovia Therapeutics

In other news, Director Colin Walsh bought 500,000 shares of the stock in a transaction on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the director owned 3,020,632 shares of the company’s stock, valued at $51,350,744. This represents a 19.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Redmile Group, Llc purchased 400,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the transaction, the insider directly owned 1,182,854 shares in the company, valued at approximately $20,108,518. This represents a 51.10% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 2,740,587 shares of company stock worth $47,269,979 over the last three months. Corporate insiders own 0.99% of the company’s stock.

Key Attovia Therapeutics News

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: Positive ATTO-1310 clinical update: Attovia reported preliminary proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b data are expected in the fourth quarter of 2026, providing a near-term catalyst. Attovia Therapeutics second-quarter results and corporate update
• Positive Sentiment: New bullish analyst coverage: LifeSci Capital initiated coverage with an “outperform” recommendation. Citigroup, Leerink Partners and Royal Bank of Canada also began coverage, increasing institutional visibility around the biotech. LifeSci Capital coverage
• Positive Sentiment: Royal Bank of Canada recently upgraded Attovia to “moderate buy,” reinforcing the positive analyst sentiment surrounding the company’s pipeline. Royal Bank of Canada upgrade
• Neutral Sentiment: Attovia’s second-quarter earnings release provides investors with an updated financial and corporate overview, with attention likely focused on development spending and the company’s ability to fund upcoming clinical work. Attovia Therapeutics earnings press release
• Negative Sentiment: Widening quarterly loss: Attovia reported a second-quarter loss of $4.88 per share, while separate coverage characterized the company’s net loss as wider than in the prior-year period. Continued losses could weigh on the stock if investors become concerned about cash needs or execution risk. Attovia Therapeutics Q2 net loss

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.